NYSE American - Delayed Quote • USD
Chromocell Therapeutics Corporation (CHRO)
At close: April 24 at 3:57 PM EDT
Pre-Market: 7:22 AM EDT
Key Executives
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Francis Knuettel II, M.B.A. | CEO, CFO, Treasurer & Secretary | 107.5k | -- | 1966 |
| Dr. Eric Lang M.D. | Chief Medical Officer | 264.99k | -- | 1963 |
Chromocell Therapeutics Corporation
4400 Route 9 South
Suite 1000
Freehold, NJ 07728
United States
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 4
Description
Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the development and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain and acute and chronic eye pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey.
Corporate Governance
Chromocell Therapeutics Corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Recent Events
- Apr 17, 2024POS EX: Post-effective amendment filed solely to add exhibits to a registration statementSee Full Filing
- Apr 16, 202410-K: Periodic Financial ReportsSee Full Filing
- Apr 15, 2024S-8: Offering RegistrationsSee Full Filing
- Apr 09, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Mar 21, 20248-K: Corporate Changes & Voting MattersSee Full Filing
Upcoming Events
Upcoming Events Information Not Available
Related Tickers
PTIX Protagenic Therapeutics, Inc.
1.6380
+5.00%
PRTG Portage Biotech Inc.
0.2502
+3.13%
BNTC Benitec Biopharma Inc.
6.72
-2.04%
ALRN Aileron Therapeutics, Inc.
4.9300
+3.79%
ANL Adlai Nortye Ltd.
13.55
+0.37%
INDP Indaptus Therapeutics, Inc.
2.3500
-5.62%
FBLG FibroBiologics, Inc.
11.52
+3.78%
TELO Telomir Pharmaceuticals, Inc.
6.97
+18.14%
CERO CERo Therapeutics Holdings, Inc.
1.4559
+7.84%
AZTR Azitra, Inc.
0.2249
-2.89%